Exozymes Inc. Joins $9M NSF-Funded Meta-PURE Initiative to Revolutionize Cell-Free Biomanufacturing with Key Industry Partners

Reuters
27 Jun
Exozymes Inc. Joins $9M NSF-Funded Meta-PURE Initiative to Revolutionize Cell-Free Biomanufacturing with Key Industry Partners

Exozymes Inc. has been selected as a core industry partner in the Meta-PURE initiative, a $9.2 million project funded by the National Science Foundation (NSF) under the CFIRE program. The initiative, led by Georgia Tech and involving a coalition of top academic and industry groups, aims to advance modular cell-free biomanufacturing. Exozymes Inc. will receive a $3 million share of the funding to develop a cell-free ATP-generating module, which will serve as a power plant for various chemical production modules. The company's involvement also includes creating a production module for santalene, a high-value fragrance compound. The project emphasizes the development of standardized, interoperable modules for diverse applications, enhancing the scalability and accessibility of cell-free systems.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1043483) on June 26, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10